- Home
- NTNX vs MRNA Comparison
NTNX vs MRNA Comparison
Compare NTNX & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTNX
- MRNA
- Stock Information
- Founded
- NTNX 2009
- MRNA 2010
- Country
- NTNX United States
- MRNA United States
- Employees
- NTNX N/A
- MRNA N/A
- Industry
- NTNX Computer Software: Prepackaged Software
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NTNX Technology
- MRNA Health Care
- Exchange
- NTNX Nasdaq
- MRNA Nasdaq
- Market Cap
- NTNX 16.8B
- MRNA 16.0B
- IPO Year
- NTNX 2016
- MRNA 2018
- Fundamental
- Price
- NTNX $65.14
- MRNA $34.06
- Analyst Decision
- NTNX Buy
- MRNA Hold
- Analyst Count
- NTNX 15
- MRNA 20
- Target Price
- NTNX $78.87
- MRNA $76.35
- AVG Volume (30 Days)
- NTNX 2.0M
- MRNA 10.5M
- Earning Date
- NTNX 02-26-2025
- MRNA 02-20-2025
- Dividend Yield
- NTNX N/A
- MRNA N/A
- EPS Growth
- NTNX N/A
- MRNA N/A
- EPS
- NTNX N/A
- MRNA N/A
- Revenue
- NTNX $2,228,718,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- NTNX $16.72
- MRNA N/A
- Revenue Next Year
- NTNX $16.91
- MRNA N/A
- P/E Ratio
- NTNX N/A
- MRNA N/A
- Revenue Growth
- NTNX 14.86
- MRNA N/A
- 52 Week Low
- NTNX $43.35
- MRNA $31.94
- 52 Week High
- NTNX $75.80
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- NTNX 52.80
- MRNA 34.88
- Support Level
- NTNX $60.92
- MRNA $33.34
- Resistance Level
- NTNX $67.23
- MRNA $35.68
- Average True Range (ATR)
- NTNX 1.69
- MRNA 2.46
- MACD
- NTNX 0.50
- MRNA -0.75
- Stochastic Oscillator
- NTNX 69.31
- MRNA 12.49
About NTNX Nutanix Inc.
Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data, anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company is into a single operating and reportable segment that is subscription-based business model. Key revenue is generated from United States.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.